Pharma Lobby Disputes Trump’s Claim That Drug Companies Are Negotiating
WASHINGTON — The pharmaceutical industry’s leading lobby group said Tuesday it did not know of a meeting at the White House to discuss lowering prescription drug prices, after President Donald Trump said executives were coming in this week to negotiate.
“We are not aware of any meeting,” said Nicole Longo, a spokeswoman for Pharmaceutical Research and Manufacturers of America.
Trump told reporters before departing to Kenosha, Wisconsin, that drug companies were coming in to see him “this week” to broker a deal “substantially” reducing drug prices. White House officials subsequently declined to comment when asked when the meeting is scheduled and who would participate.
“We’re working on drug companies on substantially lowering drug prices,” Trump said. “I’ve put out a favored nations clause, I’ve signed it. That means we get the lowest prices anywhere in the world, and we match whoever gets the lowest and the drug companies are having a real problem with that and they are coming in to see me, and we expect to get a very substantial price reduction of prescription drugs which has never been done before.”
Trump has previously claimed drug executives were ready to negotiate over his “favored nations” executive order, which purports to require drugmakers to sell medicines in the U.S. at prices comparable to those in countries with more stringent price controls.
Trump signed the order in late July, saying he would give drug companies a month to negotiate a less severe deal before it took effect and that he planned to meet with executives the following week.
The order hasn’t been published and no meeting has happened. The industry instead is running an advertising campaign criticizing Trump’s proposal.
The president, though, has repeatedly boasted of the executive order as if it was a done deal, including during remarks to the Republican National Convention last week. The White House has refused to release the actual text of the executive order.
“I did a favored nations clause, meaning we pay the same price as the lowest country that has the best deal, the companies are going crazy, the drug companies,” Trump told convention delegates last Monday in Charlotte, North Carolina.
Drugmakers did provide the White House with a counterproposal to avert the favored nations executive order last week, according to Politico. The plan reportedly would cut prices for a narrow slice of medicines — physician-administered drugs paid for by Medicare Part B — by 10%.
That’s about a third of the cuts that might be realized if prices were fully pegged to international rates.
It is expected that if the administration does push forward on Trump’s executive order it could involve months of rulemaking at various federal agencies.
The order is also expected to be limited in scope, applying only to drugs administered at a doctor’s office, not prescriptions filled at an outside pharmacy by consumers. Still, the effort has unleashed a fierce lobbying effort by the pharmaceutical industry.
Trump has taken notice of the advertisements and now frequently mentions them during campaign events, saying they are evidence that his efforts are impactful. And the president’s campaign has begun airing television ads of its own, labeling Democratic nominee Joe Biden as the drug industry’s preferred candidate.
“When you see a commercial where drug companies are taking commercials against your president, President Trump, that’s me, the only reason they’re fighting me is because I instituted very strong reforms,” Trump told supporters during a North Carolina tele-rally earlier this month.
©2020 Bloomberg News
Distributed by Tribune Content Agency, LLC.
In The News
NEW YORK (AP) — Martin Shkreli must return $64.6 million in profits he and his former company reaped from jacking... Read More
NEW YORK (AP) — Martin Shkreli must return $64.6 million in profits he and his former company reaped from jacking up the price and monopolizing the market for a lifesaving drug, a federal judge ruled Friday while also barring the provocative, imprisoned ex-CEO from the pharmaceutical... Read More
The House Oversight Committee recently released a drug pricing investigation report on the need for structural reforms. “We will continue... Read More
The House Oversight Committee recently released a drug pricing investigation report on the need for structural reforms. “We will continue our investigation on drugs, the cost of drugs and ways to make [them] more affordable for people. Right now, all of our energy needs to go... Read More
WASHINGTON — President Joe Biden reminded the public on Monday that the big social policy and climate spending bill currently... Read More
WASHINGTON — President Joe Biden reminded the public on Monday that the big social policy and climate spending bill currently in the Senate would deliver significant savings on prescription drugs for all Americans. The pitch came as Americans and Congress appear to be moving on from... Read More
WASHINGTON — An advisory panel for the Food and Drug Administration narrowly approved the use of a COVID-19 pill manufactured... Read More
WASHINGTON — An advisory panel for the Food and Drug Administration narrowly approved the use of a COVID-19 pill manufactured by Merck. If the agency accepts the recommendation, molnupiravir would be the first drug Americans could be prescribed and take at home to treat the virus.... Read More
CLEVELAND, Ohio — A landmark jury verdict Tuesday could make major pharmacy chains like CVS, Walgreens and Walmart liable for... Read More
CLEVELAND, Ohio — A landmark jury verdict Tuesday could make major pharmacy chains like CVS, Walgreens and Walmart liable for encouraging the opioid epidemic that kills thousands of Americans each year. The verdict in federal court in Ohio is the first to uphold a legal theory... Read More
SEATTLE — Testimony this week during a civil trial in Seattle could explain why opioid deaths set a record of... Read More
SEATTLE — Testimony this week during a civil trial in Seattle could explain why opioid deaths set a record of more than 100,000 in a year by last April. The class action lawsuit seeks $95 billion in damages against pharmaceutical companies that distribute the powerful painkillers.... Read More